Canada Launches ‘More Responsive’ Post-Marketing Drug Evaluation Program
Canada’s health technology appraisal body, CADTH, has launched a new program that will harness real-world evidence to provide more information and advice on the safety and effectiveness of drugs that are already approved.
You may also be interested in...
Brazil’s health technology assessment institute is to incorporate cost-effectiveness thresholds into its decision making.
Companies selling orphan medicines in the Netherlands need to prepare for the likelihood that their products will enter the so-called lock system, which means they will come under extra scrutiny and take longer to reach patients.
A joint statement from the European Medicines Agency and Heads of Medicines Agencies on biosimilar interchangeability is “concerning,” says Europe’s R&D-based industry federation, EFPIA.